Preclinical efficacy evaluations of XK-469: Dose schedule, route and cross-resistance behavior in tumor bearing mice

Investigational New Drugs

Volumn 20, Issue 1, 2002, Pages 13-22

  Polin, Lisa ^a   White, Kathryn ^a   Kushner, Juiwanna ^a   Paluch, Jennifer ^a   Simpson, Chiab ^a   Pugh, Susan ^a   Edelstein, Matthew K ^a   Hazeldine, Stuart ^a   Fontana, Joseph ^b   LoRusso, Patricia ^a   Horwitz, Jerome P ^a   Corbett, Thomas H ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antitumor; Cross resistance; Dose schedule route studies; Mice; XK 469

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; FLUOROURACIL; GEMCITABINE; UNCLASSIFIED DRUG; XB 947; XK 469;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG SCREENING; GASTROINTESTINAL DISEASE; LETHAL DOSE; MOUSE; NONHUMAN; PARALYTIC ILEUS; PRIORITY JOURNAL; STOMACH PARESIS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MICE; QUINOXALINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036207890     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014469828729     Document Type: Article

References (13)

1. Tumor models and the discovery and secondary evaluation of solid tumor active agents
2. Preclinical antitumor efficacy of analogs of XK-469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy] propionate
3. Preclinical antitumor activity of XK469 (NSC656889)
4. XK469, a selective topoisomerase 11 beta poison
5. Cis-dichlorodiammineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice
6. Establishment of cross-resistance profiles for new agents
7. Rodent models in experimental chemotherapy
8. 5-Fluorouracil containing combinations in murine tumor systems
9. Is the P388 murine tumor no longer adequate as a drug discovery model?
10. In vivo methods for screening and preclinical testing; Use of rodent solid tumors for drug discovery
11. Treatment of human prostate tumors PC-3 and TSU-PR 1 with standard and investigational agents in scid mice
12. Preclinical efficacy of thioxanthone SR-271425 against transplanted solid tumors of mouse and human origin
13. Toxicity of R(+) XK469 (NSC-698215) and S(-) XK469 (NSC-698216) in rodents and beagle dogs